Figures
Concerns were raised, post-publication, regarding common publications of the handling Academic Editor and some of the authors. A second and independent member of the PLOS ONE Editorial Board has reevaluated the manuscript and reviews, and has confirmed that the article is scientifically sound and meets PLOS ONE’s Publication Criteria. They also confirmed that there are no concerns with the original reviews.
Additionally, after publication of this article [1], the authors discovered an error in the original manuscript. Specifically, throughout the article, the “early adolescence” group was mislabeled and inadvertently included all participants who accessed GAH prior to age 16, including some respondents who accessed GAH at ages younger than what is recommended in the most recent Endocrine Society Guidelines. Analyses for this “early adolescence” group have been updated to include only those who accessed GAH during the younger adolescent age group outlined by the most recent Endocrine Society guidelines (i.e., ages 13–15) [2]. The following specific errors have been corrected:
- The early adolescence group age (14–16) appears incorrectly throughout the article. The correct group age is (13–15). The Endocrine Society Guidelines note an age of 13.5, and the authors chose age 13 as a lower cutoff to include individuals who would have accessed GAH at this age.
- The number and percentage of the early adolescent group reporting access to GAH appears incorrectly through the article. The correct values are 99 (0.5%).
- The sample of individuals ever desiring GAH appears incorrectly throughout the article as 21,598. The correct value is 21,578, now that those reporting access to GAH younger than age 13 have been excluded.
The following sentence has been added to the first paragraph of the Methods section: We additionally excluded any participants who reported accessing GAH prior to age 13, as this would represent an age lower than the current threshold mentioned in the most recent Endocrine Society Guidelines.
Please see S1 Table for detailed in-text corrections and locations.
This error impacted Tables 1–5. In Table 3, there was an additional error in the third column, which has also been corrected here. Please see the correct tables below.
These errors do not affect the results of the primary analyses or conclusions reported in the article.
Finally, the analysis code underlying results in this article was not included with the published article. With this Correction, the authors provide the code as S1 File.
A member of PLOS ONE’s Editorial Board confirmed that the new results support the results and conclusions of the published article.
The authors apologize for the errors in the published article.
References
- 1. Turban JL, King D, Kobe J, Reisner SL, Keuroghlian AS (2022) Access to gender-affirming hormones during adolescence and mental health outcomes among transgender adults. PLoS ONE 17(1): e0261039. https://doi.org/10.1371/journal.pone.0261039 pmid:35020719
- 2. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. (2017) Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2017;102(11):3869–903.
Citation: Turban JL, King D, Kobe J, Reisner SL, Keuroghlian AS (2023) Correction: Access to gender-affirming hormones during adolescence and mental health outcomes among transgender adults. PLoS ONE 18(6): e0287283. https://doi.org/10.1371/journal.pone.0287283
Published: June 12, 2023
Copyright: © 2023 Turban et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.